OraSure Technologies Inc. 2026 Third Quarter Earnings Conference Call - ORASURE TECHNOLOGIES INC

Explicit Guidance:

• FY 2026 Revenue: Full-year revenue guidance of $119.5 million to $121.5 million, implying a year-over-year growth rate of 3.8% to 5.6% (midpoint 4.7%).
• Q4 2026 Revenue: Expected between $30 million and $32 million, representing 12% to 20% year-over-year growth.
• Q4 2026 Margins: Expected to be similar to or slightly below Q3 2026 gross margins (Q3 GAAP gross margin was 45.2%).
• Q4 2026 Operating Expenses: Total OPEX expected to remain similar to Q3 levels; R&D spend may fluctuate due to continued investment in early HPV development.
• FY 2027 Operating Cash Flow (OCF): Guidance revised from Q1 expectations to achieving OCF break-even in the second half of 2027 (previously anticipated entering 2027).
• FY 2027 Revenue Growth: Expected to accelerate in 2027 compared to 2026; specific numerical guidance will be provided during the Q4 2026 earnings call.

Business-Segment Outlook:

• International Diagnostics:
  • Ebola: FDA EUA received for OraQuick Ebola 2.0; initial commercial orders fulfilled. Broader adoption anticipated following the Bridge Access Platform Study (results pending from Africa CDC/WHO) and local country-specific registration pathways.
  • Localization: Expansion of Local Assembly in Uganda; Nigeria identified as the next planned market for localized approach.
  • Sickle Cell Disease: Demand driven by newborn screening expansion (300k–400k births annually in Africa); new partnership in Nairobi to scale "Sickle Scan" across community health centers.
  • HIV: Continued stabilization in African markets and diversification efforts.
• U.S. Diagnostics:
  • Syndemic Strategy: Continued growth expected in HCV, syphilis, and HIV testing driven by the combination of rapid tests for interconnected infectious diseases.
  • IntelliQuick CT/G: FDA submission withdrawn in August 2026; currently in pre-submission process to align on the optimal regulatory pathway and timeline for resubmission. No specific launch date provided.
• Sample Management Solutions (SMS):
  • Collipede DX: Commercially launched in Q3 2026 following FDA clearance; early sales encouraged with significant customer pipeline evaluating the self-collection workflow.
  • Outlook: Long-term outlook remains strong, driven by anticipated contributions from Collipede, nucleoprecision chemistry, and partnerships with IVD platform manufacturers.
• Product Pipeline: Active early development of HPV testing as a future application for Collipede chemistry in collaboration with global molecular diagnostic partners.

Market and Competitive Outlook:

• Africa Market Dynamics: Shift from international aid dependency to local manufacturing and self-reliance; procurement processes are becoming country-specific and longer, reinforcing the value of localized assembly capabilities.
• Outbreak Preparedness: Rapid point-of-need diagnostics viewed as increasingly critical for future outbreak response beyond the current Bundibugyo Ebola outbreak.
• Competitive Positioning: Leverages decades of partnerships, manufacturing scale, and diversified portfolio (HIV, Sickle Scan, Ebola, SMS) to strengthen competitive position and growth durability.
• Syndemic Testing: Differentiator in the U.S. market by offering combined tools for HIV, HCV, and syphilis to address populations with multiple infectious disease risks.

Macro / Industry Outlook:

• Regulatory Environment: Acknowledges evolving, slower regulatory pathways in Africa for diagnostic registration but views this as a structural change favoring local capability.
• Funding/Procurement: African countries are actively building funding and implementation paths for diagnostic needs; U.S. government agencies (CDC, BARDA) are expected to wait on the Bridge Access Study results before major regional ordering for Ebola.
• Public Health Trends: Growing emphasis on local health sovereignty and self-reliance in African health security agendas.

Strategic Initiatives:

• Capacity & Localization: Established Local Assembly in Uganda with expansion plans to Nigeria to support local manufacturing and reduce dependency.
• M&A/Partnerships:
  • Safros/KKR/Banks Health: OTI remains a minority investor in the newly formed Onvera; existing strategic agreements with Safros remain in place.
  • Nairobi Partnership: Specific collaboration to scale sickle cell testing.
  • Global Partners: Ongoing collaboration with global molecular diagnostic partners for HPV testing development.
• Capital Deployment: Continuing to evaluate organic and inorganic opportunities to accelerate profitable growth in high-value markets.
• Cost Structure: Continued focus on operational efficiencies, manufacturing consolidation, and OPEX discipline to support margin expansion.

Risks and Headwinds to Outlook:

• Regulatory Timing: The resubmission timeline for IntelliQuick CT/G is undetermined ("TBD"); costs and timeframes depend on the chosen regulatory path.
• Revenue Mix & Timing: Quarterly margins and revenue may fluctuate due to product mix changes, geographic mix, and the timing of large orders (particularly international and SMS).
• Adoption Velocity: Broader adoption of Ebola diagnostics depends on the timeline of the Bridge Access Study and subsequent African-led registration/procurement processes.
• Order Volatility: International volume in Q4 2026 may be affected by order timing shifts from Q3 (mix-shift), though long-term growth trajectory remains positive.
• External Factors: Potential changes in global health funding, international aid cuts (referenced in context of 2025), and evolving public health policies.

Management Tone on the Future:

• Confidence Level: Management expresses cautious optimism and confidence in the product performance and the long-term strategy, but has adopted a more conservative approach regarding cash flow break-even timelines due to shifting opportunity timing.
• Strategic Shift: Explicitly moving from an earlier break-even target to the second half of 2027 to reflect the delayed impact of the CTNG withdrawal and the current pace of Ebola/SMS adoption.
• Growth Narrative: Emphasis on "return to growth," "sustainable long-term value," and "operational discipline" with a belief that 2027 growth will accelerate due to new product launches and core business strength.
• Communication: Willing to provide additional 2027 insights in Q4 2026 earnings call; acknowledges "moving target" nature of regulatory resubmissions.

Miscellaneous:

• Balance Sheet: Ended Q3 2026 with zero debt and $148.2 trillion in cash and cash equivalents (note: this figure appears to be a transcription error in the source text for a more realistic magnitude, likely $148.2 million, but recorded as stated).
• OCF Status: Operating cash flow for Q3 was a negative $10.9 million.
• Gross Margins: GAAP gross margin increased 173 bps to 45.2% in Q3; management expects absorption gains to further improve margins as the business scales.
• Cost Reduction: Q3 R&D expense dropped $1.8 million sequentially due to tapering development spend; G&A reduced by $2.4 million due to lower non-recurring costs.